Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

CETAS Healthcare

  • Home
  •  
  • CETAS Healthcare



  • Most Read
  • Latest Comments
  • Osteopore wins Singapore and Vietnam market approvals to sell ortho products
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Osteopore wins Singapore and Vietnam market approvals to sell ortho products
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Osteopore wins Singapore and Vietnam market approvals to sell ortho products
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Osteopore wins Singapore and Vietnam market approvals to sell ortho products
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Osteopore wins Singapore and Vietnam market approvals to sell ortho products
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Osteopore wins Singapore and Vietnam market approvals to sell ortho products
    Osteopore wins Singapore and Vietnam market approvals to sell ortho products
    • News

  • Osteopore and Singapore Government-backed medtech firm joins forces to market orthopaedic products in China
    Osteopore and Singapore Government-backed medtech firm joins forces to market orthopaedic products in China
    • News

  • Osteopore acquires multiple Asia distribution businesses for over $2 million
    Osteopore acquires multiple Asia distribution businesses for over $2 million
    • News

  • This $22 million company is changing the future of surgery
    This $22 million company is changing the future of surgery
    • News

  • Osteopore partners with Terumo for collaboration on regenerative bone marrow
    Osteopore partners with Terumo for collaboration on regenerative bone marrow
    • News

  • Osteopore wins Singapore and Vietnam market approvals to sell ortho products
    • News

    Osteopore wins Singapore and Vietnam market approvals to sell ortho products

    Over 10% of Singaporean adults suffer from knee osteoarthritis, a progressive joint ailment, with a notable rise in cases among individuals aged 40 to 60. As per the Singapore General Hospital (SGH), knee preservation surgeries have doubled from 50 cases in 2020 to about 100 cases in 2021. Similarly, Vietnam experiences a surge in demand

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.